Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol + MTX Follow-up in RA
NCT01197066Phase 3Completed
- Sponsor
- Otsuka Holdings
- Start
- Mar 2010
- Primary completion
- Nov 2016
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by Otsuka Holdings. Started Mar 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01197066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01197066.